SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-039029
Filing Date
2023-05-12
Accepted
2023-05-12 16:15:38
Documents
50
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0323_virpaxpharma.htm   iXBRL 10-Q 475726
2 CERTIFICATION f10q0323ex31-1_virpaxpharma.htm EX-31.1 9687
3 CERTIFICATION f10q0323ex31-2_virpaxpharma.htm EX-31.2 9704
4 CERTIFICATION f10q0323ex32-1_virpaxpharma.htm EX-32.1 5727
  Complete submission text file 0001213900-23-039029.txt   2839283

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE vrpx-20230331.xsd EX-101.SCH 35311
6 XBRL CALCULATION FILE vrpx-20230331_cal.xml EX-101.CAL 14699
7 XBRL DEFINITION FILE vrpx-20230331_def.xml EX-101.DEF 136008
8 XBRL LABEL FILE vrpx-20230331_lab.xml EX-101.LAB 287192
9 XBRL PRESENTATION FILE vrpx-20230331_pre.xml EX-101.PRE 148747
44 EXTRACTED XBRL INSTANCE DOCUMENT f10q0323_virpaxpharma_htm.xml XML 257012
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40064 | Film No.: 23915906
SIC: 2834 Pharmaceutical Preparations